A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

PHASE2CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

November 7, 2017

Primary Completion Date

August 19, 2019

Study Completion Date

August 19, 2019

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

IW-1973

Oral Tablet

DRUG

Placebo Oral Tablet

Oral Tablet

Trial Locations (62)

10025

Mount Sinai School of Medicine, New York

17602

Research Institute of Lancaster General Health, Lancaster

19102

Drexel University College of Medicine, Philadelphia

23298

Virginia Commonwealth University Medical College of Virginia, Richmond

27710

Duke University Medical Center, Durham

32127

Progressive Medical Research, Port Orange

32216

East Coast Institute for Research, Jacksonville

33016

New Generation of Medical Research, Hialeah

33024

Broward Research Center, Pembroke Pines

33126

PCRS Network, LLC, Miami

33308

Holy Cross Hospital, Fort Lauderdale

37232

Vanderbilt University Medical Center, Nashville

43210

Ohio State University Medical Center (OSUMC), Columbus

43606

ProMedica Toledo Hospital, Toledo

46237

Franciscan Physician Network - Indiana Heart Physicians, Indianapolis

48197

Michigan Heart, Ypsilanti

53713

Unity Point Health, Madison

53792

University of Wisconsin - Madison, Madison

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

61602

Unity Point Health - Methodist Hospital, Peoria

63106

VA Healthcare John Cochran Medical Center, St Louis

63110

Washington University, St Louis

66160

University of Kansas Medical Center, Kansas City

70427

Lousiana Heart Center, Bogalusa

72204

Cardiology and Medicine Clinic, Little Rock

73135

South Oklahoma Heart Research, Oklahoma City

73159

Newton Clinical Research, Oklahoma City

74104

Oklahoma Heart Institute, Tulsa

75069

North Dallas Research Associates, Dallas

75231

Texas Health Research and Education Insitute, Dallas

75235

Southwest Family Medicine Associates, Dallas

75246

Baylor University Medical Center, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

78229

Schnitzler Cardiovascular Consultants, San Antonio

80120

South Denver Cardiology Associates, Littleton

80218

Aurora Denver Cardiology, Denver

83712

St. Luke's Regional Medical Center, Boise

85016

Arizona Arrhythmia Research Center, Phoenix

85259

Mayo Clinic, Scottsdale

85724

University of Arizona, Tucson

90036

Axis Clinical Trials, Los Angeles

90509

Harbor UCLA Medical Center, Torrance

91325

Valley Clinical Trials, Northridge

91941

JEHM, La Mesa

91950

JEHM, National City

94305

Stanford University, Palo Alto

97239

Oregon Health & Science University (OHSU), Portland

97477

PeaceHealth, Sacred Heart Physicians, Springfield

98431

Madigan Army Medical Center, Tacoma

02111

Tufts Medical Center, Boston

02114

Massachusetts General Hospital, Boston

02118

Boston University School of Medicine, Boston

01805

Lahey Clinic, Burlington

07450

The Valley Hospital, Ridgewood

05401

University of Vermont Medical Center, Burlington

N6A 5A5

London Health Sciences Centre, London

M5G 1X5

Mount Sinai Hospital, Toronto

G7H 7K9

Ecogene-21, Chicoutimi

J1G 2E8

CIUSSS de l'Estrie - CHUS, Sherbrooke

G1V 4G5

Institut Universitaire de Cardiologie et de Pneumologie De Quebec, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cyclerion Therapeutics

INDUSTRY

lead

Akebia Therapeutics

INDUSTRY

NCT03254485 - A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) | Biotech Hunter | Biotech Hunter